Koers Apyx Medical Corp Nasdaq
Aandelen
US03837C1062
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 50,01 mln. 46,69 mln. | Omzet 2025 * | 54,77 mln. 51,13 mln. | Marktkapitalisatie | 46,42 mln. 43,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,27 mln. | Nettowinst (verlies) 2025 * | -24 mln. -22,41 mln. | EV/omzet 2024 * | 0,93 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,85 x |
K/w-verhouding 2024 * |
-1,77
x | K/w-verhouding 2025 * |
-1,96
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 82,03% |
Recentste transcriptie over Apyx Medical Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Charles Goodwin
CEO | Chief Executive Officer | 58 | 15-12-17 |
Matthew Hill
DFI | Director of Finance/CFO | 56 | 04/12 |
Kari Larson
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lawrence Waldman
BRD | Director/Board Member | 77 | 15-03-11 |
Craig Swandal
BRD | Director/Board Member | 63 | 09-03-18 |
John Andres
BRD | Director/Board Member | 66 | 17-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-5,60% | 181 mld. | |
-4,45% | 101 mld. | |
-4,15% | 67,54 mld. | |
-8,63% | 45,09 mld. | |
+9,70% | 44,37 mld. | |
+6,13% | 40,7 mld. | |
+15,22% | 29,85 mld. | |
+14,80% | 24,49 mld. | |
-6,46% | 23,99 mld. |